Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan

Phase 2 Completed 215 enrolled Aerie Pharmaceuticals

RandomizedParallel-groupDouble-blindTreatment

Summary

Test ocular hypotensive efficacy and systemic safety of netarsudil 0.01%, 0.02%, 0.04% relative to placebo in subjects with open-angle glaucoma or ocular hypertension in Japan

Timeline

Start: 2019-03-19
Primary completion: 2019-09-19
Completion: 2019-09-19

Publications

Araie M, Sugiyama K, Aso K, Kanemoto K, Kothapalli K, Kopczynski C, Senchyna M, Hollander DA. Phase 2 Randomized Clinical Study of Netarsudil Ophthalmic Solution in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension. Adv Ther. 2021 Apr;38(4):1757-1775. doi: 10.1007/s12325-021-01634-9. Epub 2021 Feb 24.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Netarsudil	Small molecule	0.01 %	Topical
Subject	Netarsudil	Small molecule	0.02 %	Topical
Subject	Netarsudil	Small molecule	0.04 %	Topical

Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan

Summary

Timeline

Publications

Drugs

Indications